View Systems, Inc. (VSYM) Enters into Definitive Agreement to Acquire Y.M. Advantage, Inc.

Earlier today, View Systems, Inc. (OTC: VSYM), a manufacturer and installer of non-invasive weapons detection systems for government and commercial use, announced it has entered into a definitive agreement to acquire Y.M. Advantage, Inc. (YMA), a private corporation engaged in the acquisition, development and management of medical clinics providing treatment for various medical issues. Through this acquisition, View Systems aims to achieve greater market penetration while promoting sustainable financial growth.

“As previously announced, our exploration and execution of M&A agreements are by no means an exit from our current focus of operations,” Gunther Than, chief executive officer of View Systems, stated in the news release. “After careful selection and due diligence, we’re excited to announce our acquisition of YMA, which will help View Systems gain traction in obtaining exposure, application and market penetration of our products.”

YMA’s business model focuses primarily on the acquisition of concierge, all-inclusive medical practices, particularly those relating to issues of male sexual dysfunction – including erectile dysfunction, testosterone replacement therapy and premature ejaculation. By targeting this niche in the medical community, YMA seeks to capitalize on current market trends that are being magnified by the aging population and a sharp rise in the prevalence of certain medical conditions.

Market statistics support YMA’s strategy. According to a report by Transparency Market Research, the increasing incidence of genitourinary diseases and a shifting preference toward a sedentary lifestyle represent lucrative opportunities in the male sexual dysfunction market moving forward. The company estimates the current U.S. market for erectile dysfunction at $6 billion, and aging baby boomers are expected to provide an expanding pool of prospective clients over the next decade.

In the past, major pharmaceutical companies Pfizer (NYSE: PFE) and Eli Lilly and Company (NYSE: LLY) have led the way in the male sexual dysfunction market with Viagra and Cialis, respectively, but projections suggest that this could be set to change in the coming years. While Viagra will maintain patent exclusivity until 2020, it is one of the final holdouts in the market. As exclusivities expire, industry data suggests that there will be an opportunity for new players to grab market share with innovative new drugs addressing medical conditions that are increasingly prevalent throughout the aging population. This should ensure that YMA’s targeted medical practices remain in high demand for the foreseeable future.

“Our board of directors consists of physicians who are well versed in the medical arena and have started and successfully operated clinics and medical practices,” continued Than. “They believe that this acquisition will dramatically enhance our revenue and provide for a wider ranging business practice.”

Look for View Systems to leverage the high demand for treatments related to male sexual dysfunction in order to promote strong financial growth. By acquiring YMA and maintaining its current focus of operations, the company becomes a diversified investment opportunity with tremendous upside for prospective shareholders.

For more information, visit www.viewsystems.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net